Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Apr 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how different levels of oxygen can help improve the health of very premature infants who have a condition called bronchopulmonary dysplasia. This condition affects their lungs and can lead to a serious problem known as pulmonary hypertension, which can be life-threatening. The goal of the study is to find out if adjusting the amount of oxygen these babies receive can lead to better outcomes, helping to reduce the risks associated with these conditions.

To participate in this trial, infants need to be born extremely premature, between 22 weeks and 31 weeks of gestation, and have a diagnosis of pulmonary hypertension based on specific heart tests. They also need to be receiving extra oxygen and have certain eye conditions related to their prematurity. The trial is not yet recruiting participants, but once it begins, families of eligible infants can expect to have their baby's oxygen levels carefully monitored and adjusted as part of the study. This research is important because it may help doctors understand the best ways to care for these vulnerable infants and improve their chances for a healthier future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Between 22w 0/7d and 31w 6/7d gestation at birth
• • Diagnosed with echocardiographic pulmonary hypertension (1) \>20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index \>1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg
• • Receiving supplemental oxygen
• • Have mature retinas
• Exclusion Criteria:
• • Major congenital anomalies